TRDA - NASDAQ
Entrada Therapeutics, Inc.
$6.58
-0.90%Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotEntrada Therapeutics, Inc. Management Team
Ms. Karla MacDonald
Chief Corporate Affairs Officer
Mr. Dipal Doshi
Chief Executive Officer & Director
Compensation
$959,310
Mr. Kory James Wentworth CPA
Chief Financial Officer & Treasurer
Mr. Leo Qian Ph.D.
Co-Founder & Vice President of Discovery Research
Dr. Jared Cohen J.D., Ph.D.
General Counsel
Mr. Nathan J. Dowden
President & Chief Operating Officer
Compensation
$709,810
Dr. Natarajan Sethuraman Ph.D.
President of Research & Development
Compensation
$727,192
Ms. Kerry Robert M.S.
Senior Vice President of People
Mr. Kevin Healy Ph.D.
Senior Vice President of Regulatory Affairs
Murali Mallem
Vice President & Head of CMC
Entrada Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $990K and sold $5.40M worth of TRDA shares, resulting in $4.41M of net selling activity.
3 Months
5.0K
29.32K
74.9K
1.07M
-1.0M
-$1.04M
3-6 Months
0
0.00
8.0K
97.89K
-98K
-$98K
6-9 Months
24.6K
210.12K
408.9K
3.61M
-3.4M
-$3.40M
9-12 Months
95.0K
750.50K
92.1K
625.10K
+125K
+$125K
Top Buyers
Baker Bros. Advisors Lp
10 Percent Owner
$210K
Zeiher Bernhardt G
Director
$179K
Kim Peter S
Director
$150K
Thistle Mary
Director
$150K
Chapman Gina
Director
$150K
Top Sellers
Parmar Kush
Director, 10 Percent Owner:
$2.03M
5Am Ventures V, L.P.
10 Percent Owner
$2.03M
Wentworth Kory James
Officer: Chief Financial Officer
$443K
Dowden Nathan J
Officer: President & Coo
$435K
Sethuraman Natarajan
Officer: President, Research & Develop.
$408K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $4.41M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
TRDA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 10, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 13, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 25, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 19, 2022 | June 02, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.